Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Pharmacol., 11 December 2025

Sec. Translational Pharmacology

Volume 16 - 2025 | https://doi.org/10.3389/fphar.2025.1678203

Correction: Cimifugin suppresses NF-κB signaling to prevent osteoclastogenesis and periprosthetic osteolysis

This article is a correction to:

  1. Cimifugin Suppresses NF-κB Signaling to Prevent Osteoclastogenesis and Periprosthetic Osteolysis

    1. Read original article
Juan DuanJuan Duan1Xuantao HuXuantao Hu2Tao LiTao Li2Gen WuGen Wu2Pengcheng Dou Pengcheng Dou2*Zhengxiao Ouyang Zhengxiao Ouyang2*
  • 1Department of Geriatric Internal Medicine, The Second Xiangya Hospital, Central South University, Changsha, China
  • 2Deparment of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, China

A Correction on
Cimifugin suppresses NF-κB signaling to prevent osteoclastogenesis and periprosthetic osteolysis

by Duan J, Hu X, Li T, Wu G, Dou P, Ouyang Z. Front Pharmacol. 2021;12:724256. doi: 10.3389/fphar.2021.724256

There was a mistake in Figure 1E (80 μM group) and Figure 2C (80 μM group) as published. Due to an error during figure preparation, the image used for the 80 μM group in Figure 1E (TRAP staining of BMMs) and the 80 μM group in Figure 2C (F-actin immunofluorescence) were incorrect and do not represent the appropriate experimental data. The corrected Figure 1 and Figure 2 appears below.

Figure 1
Illustration of a chemical structure labeled

Figure 1. CIM at a noncytotoxic dose inhibits RANKL-induced osteoclast formation in RAW264.7 and BMM cell lineages in a dose-dependent manner. (A) The chemical structure of CIM. (B) The cell viability of BMMs treated with CIM at different doses for 48 or 96 h. CIM at doses less than or equal to 320 μM was identified as noncytotoxic. (C) and (E) TRAP staining images of RAW264.7 cells and BMMs incubated with CIM at gradient concentrations for 5–7 days. The numbers (D) and areas (F) of TRAP + osteoclasts were quantified and analyzed. (*: p < 0.05; **: p < 0.01 compared with the control group).

Figure 2
Images with panels A, B, C, and D showing effects of varying concentrations on cell behavior and structure:A: Microscopic images of surfaces under control and three concentrations (80 µM, 160 µM, 320 µM) showing changes in resorption pits.B: Bar graph displaying a reduction in resorption pit area relative to the control across increasing concentrations of CIM.C: Fluorescent images showing F-actin distribution in cells for control, 80 µM, and 320 µM concentrations, highlighting structural changes.D: Two bar graphs comparing the number and area of F-actin rings across control and concentrations, showing significant reductions, particularly at 320 µM.

Figure 2. Noncytotoxic CIM dose-dependently mitigates the bone-resorbing activity of osteoclasts in vitro. (A) Scanning electron microscopy images of eroded surfaces on bone slices treated with CIM at the indicated concentrations. (B) The areas of bone resorption pits relative to the control group are shown. (C) Immunofluorescence images of F-actin rings (in green) inBMM-derived osteoclasts treated with CIMat the indicated doses. (**: p < 0.01 compared with the control group). (D) Number and area of F-actin ring were counted via Image J Software.

The original article has been updated

Generative AI statement

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: osteoclast, NF-κB, p38, MAPK, aseptic prosthetic loosening, periprosthetic osteolysis, cimifugin

Citation: Duan J, Hu X, Li T, Wu G, Dou P and Ouyang Z (2025) Correction: Cimifugin suppresses NF-κB signaling to prevent osteoclastogenesis and periprosthetic osteolysis. Front. Pharmacol. 16:1678203. doi: 10.3389/fphar.2025.1678203

Received: 02 August 2025; Accepted: 02 December 2025;
Published: 11 December 2025.

Edited and reviewed by:

Nathan Pavlos, University of Western Australia, Australia

Copyright © 2025 Duan, Hu, Li, Wu, Dou and Ouyang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Pengcheng Dou, ZG91cGVuZ2NoZW5nQGNzdS5lZHUuY24=; Zhengxiao Ouyang, b3V5YW5nemhlbmd4aWFvQGNzdS5lZHUuY24=

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.